

8 February 2017

## Successful completion of Less Than Marketable Parcel Share Sale Program

- 1,164 less than marketable parcels (LTMP) sold, representing 3,783,086 shares;
- Participating shareholders to receive 3.8 cents per share;
- Shareholder base reduced to approximately 1,504 shareholders.

Antisense Therapeutics Limited (ASX: ANP or “the Company”) is pleased to announce that it has completed the sale of shares for holders of LTMP in the Company.

A total of 1,164 shareholders, with an aggregate of 3,783,086 shares participated in the program. The shares were sold as an off market transaction at a price of 3.8 cents per share (being a 5.6% premium to the market closing price on the sale date 3 February 2017). It is anticipated that the proceeds are to be distributed to participants during the week commencing 13 February 2017.

Mark Diamond, CEO of Antisense Therapeutics noted: “We are pleased with the result of the LTMP program, which will reduce ongoing administrative costs and at the same time, has provided an opportunity for a significant number of shareholders to sell their relatively small shareholdings with no commission payable. ANP appreciates the support of the investors in purchasing the shares as we look to progress our clinically advanced development programs and add new growth opportunities to complement our existing product pipeline.”

### Contact Information:

Website: [www.antisense.com.au](http://www.antisense.com.au)

Antisense Therapeutics office +61 (0)3 9827 8999

**Antisense Therapeutics Limited** (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed From Ionis Pharmaceuticals Inc. (formerly Isis Pharmaceuticals Inc.), a world leader in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHr production which in a Phase II clinical trial successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the preclinical stage being investigated as a potential treatment for cancer.